July 30, 2013
Janssen Pharmaceutical announced on July 26 that it filed on the same day a new drug application (NDA) for its prostate cancer treatment abiraterone acetate for the treatment of patients with castration-resistant prostate cancer (CRPC) in Japan. The drug has...read more